PR90423

HAIFA, Israel and MIAMI, July 5, 2021 /PRNewswire=KYODO JBN/ --

Positive momentum continues to bring Focused Ultrasound to global patients

living with Essential Tremor and Tremor-dominant Parkinson's Disease

Insightec(R) [ http://www.insightec.com/ ], a global healthcare company focused

on creating the next generation of patient care, announced approval of the

Exablate(R) Neuro platform by the Health Sciences Authority (HSA) in Singapore.

The Exablate Neuro (Exablate 4000) platform uses Focused Ultrasound to ablate a

target deep in the brain. The unilateral treatment is suitable for patients

with Essential Tremor (age 22 or older) or Tremor-dominant Parkinson's Disease

(age 30 or older) who have not responded to medications.

"The value of Focused Ultrasound for medical centers treating movement

disorders is greatly improved patient care," said Maurice R. Ferré MD,

Insightec CEO and Chairman of the Board of Directors. "Our technology enables

patients to go from a life dominated by tremor to the potential for a calm,

steady hand."

There are 81 leading medical centers globally that have established Focused

Ultrasound programs with Exablate Neuro. Insightec is working with Transmedic [

http://www.transmedicgroup.com/ ]Group, a leading distributor of advanced

medical technology in Southeast Asia, to advance adoption of the Exablate Neuro

in the Singapore market.  

"We are excited to bring this transformational technology to medical centers in

Singapore," commented Teo Kee Meng, Transmedic Managing Director.  "More

importantly, patients will now have the option to choose a treatment that is

outpatient and incisionless."

About Insightec

Insightec is a global healthcare company creating the next generation of

patient care by realizing the therapeutic power of acoustic energy. The

company's Exablate(R) Neuro platform focuses sound waves, safely guided by MRI,

to provide tremor treatment to patients with Essential Tremor and

Tremor-dominant Parkinson's Disease. Research for future applications in the

neuroscience space is underway in partnership with leading academic and medical

institutions. Insightec is headquartered in Haifa, Israel, and Miami, with

offices in Dallas, Shanghai and Tokyo.

Follow us on  Facebook [ https://www.facebook.com/INSIGHTEC.MRgFUS/ ], LinkedIn

[ https://www.linkedin.com/company/insightec/ ]and Twitter [

https://twitter.com/INSIGHTEC ]or visit www.insightec.com for more information.

Forward-looking Statements

This document contains forward-looking statements regarding, among other

things, plans, expectations, and future events.  In some cases, forward-looking

statements can be identified by the following words: "may," "can," "will,"

"could," "would," "should," "expect," "intend," "plan," "anticipate,"

"believe," "estimate," "predict," "project," "potential," "promise,"

"continue," "ongoing," or the negative of these terms. Forward-looking

statements involve known and unknown risks, uncertainties and other important

factors that could cause actual results to differ materially from what is

expressed or implied by the statements. Any forward-looking statement is based

on information available to Insightec as of the date of the statement. All

written or oral forward-looking statements attributable to Insightec are

qualified by this caution. Insightec does not undertake any obligation to

update or revise any forward-looking statement to reflect any change in

circumstances or in Insightec's expectations.

"Exablate," and "Exablate Neuro," as well as the "INSIGHTEC" logo, whether

standing alone or in connection with the word " Insightec", are protected

trademarks of Insightec.

Insightec Media Contact

G&S Business Communications for Insightec

Elizabeth Mannheimer

+1 917.595.3034

emannheimer@gscommunications.com

Logo - https://mma.prnewswire.com/media/1120780/Insightec_Logo.jpg

Source: Insightec